Диссертация (1140892), страница 25
Текст из файла (страница 25)
‒ 2016. ‒ T. 30, № 12. ‒ C. 2342-2350.199. Garcia-Montero A. C., Jara-Acevedo M., Alvarez-Twose I., Teodosio C., Sanchez-Munoz L.,Muniz C., Munoz-Gonzalez J. I., Mayado A., Matito A., Caldas C., Morgado J. M., EscribanoL., Orfao A. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemicmastocytosis are associated with disease progression // Blood.
‒ 2016. ‒ T. 127, № 6. ‒ C.761-8.200. Pardanani A., Lim K. H., Lasho T. L., Finke C., McClure R. F., Li C. Y., Tefferi A.Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated withother myeloid malignancies // Blood. ‒ 2009. ‒ T. 114, № 18. ‒ C. 3769-72.201.
Valent P., Sperr W. R., Akin C. How I treat patients with advanced systemic mastocytosis //Blood. ‒ 2010. ‒ T. 116, № 26. ‒ C. 5812-7.145202. Valent P., Sotlar K., Sperr W. R., Escribano L., Yavuz S., Reiter A., George T. I., KluinNelemans H. C., Hermine O., Butterfield J. H., Hagglund H., Ustun C., Hornick J. L.,Triggiani M., Radia D., Akin C., Hartmann K., Gotlib J., Schwartz L. B., Verstovsek S., OrfaoA., Metcalfe D. D., Arock M., Horny H. P.
Refined diagnostic criteria and classification ofmast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal //Ann Oncol. ‒ 2014. ‒ T. 25, № 9. ‒ C. 1691-700.203. Georgin-Lavialle S., Lhermitte L., Dubreuil P., Chandesris M. O., Hermine O., Damaj G. Mastcell leukemia // Blood. ‒ 2013. ‒ T. 121, № 8.
‒ C. 1285-95.204. Muller U. R., Haeberli G. The problem of anaphylaxis and mastocytosis // Curr Allergy AsthmaRep. ‒ 2009. ‒ T. 9, № 1. ‒ C. 64-70.205. Gonzalez de Olano D., de la Hoz Caballer B., Nunez Lopez R., Sanchez Munoz L., CuevasAgustin M., Dieguez M. C., Alvarez Twose I., Castells M. C., Escribano Mora L. Prevalenceof allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis inSpain: a study of the Spanish network on mastocytosis (REMA) // Clin Exp Allergy. ‒ 2007. ‒T.
37, № 10. ‒ C. 1547-55.206. Florian S., Krauth M. T., Simonitsch-Klupp I., Sperr W. R., Fritsche-Polanz R., Sonneck K.,Fodinger M., Agis H., Bohm A., Wimazal F., Horny H. P., Valent P. Indolent systemicmastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severeanaphylactoid episodes // Int Arch Allergy Immunol. ‒ 2005. ‒ T. 136, № 3. ‒ C. 273-80.207. Brockow K., Jofer C., Behrendt H., Ring J.
Anaphylaxis in patients with mastocytosis: a study onhistory, clinical features and risk factors in 120 patients // Allergy. ‒ 2008. ‒ T. 63, № 2. ‒ C.226-32.208. Gulen T., Hagglund H., Dahlen B., Nilsson G. High prevalence of anaphylaxis in patients withsystemic mastocytosis - a single-centre experience // Clin Exp Allergy. ‒ 2014. ‒ T. 44, № 1.
‒C. 121-9.209. Morgado J. M., Perbellini O., Johnson R. C., Teodosio C., Matito A., Alvarez-Twose I.,Bonadonna P., Zamo A., Jara-Acevedo M., Mayado A., Garcia-Montero A., Mollejo M.,George T. I., Zanotti R., Orfao A., Escribano L., Sanchez-Munoz L. CD30 expression by bonemarrow mast cells from different diagnostic variants of systemic mastocytosis //Histopathology.
‒ 2013. ‒ T. 63, № 6. ‒ C. 780-7.210. Kovalszki A., Weller P. F. Eosinophilia in mast cell disease // Immunol Allergy Clin North Am. ‒2014. ‒ T. 34, № 2. ‒ C. 357-64.146211. Travis W. D., Li C. Y., Bergstralh E. J., Yam L. T., Swee R. G. Systemic mast cell disease.Analysis of 58 cases and literature review // Medicine (Baltimore). ‒ 1988. ‒ T. 67, № 6.
‒ C.345-68.212. Pardanani A., Brockman S. R., Paternoster S. F., Flynn H. C., Ketterling R. P., Lasho T. L., Ho C.L., Li C. Y., Dewald G. W., Tefferi A. FIP1L1-PDGFRA fusion: prevalence andclinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia //Blood. ‒ 2004. ‒ T. 104, № 10. ‒ C.
3038-45.213. Klion A. D., Robyn J., Akin C., Noel P., Brown M., Law M., Metcalfe D. D., Dunbar C., NutmanT. B. Molecular remission and reversal of myelofibrosis in response to imatinib mesylatetreatment in patients with the myeloproliferative variant of hypereosinophilic syndrome //Blood. ‒ 2004. ‒ T. 103, № 2. ‒ C. 473-8.214. Pardanani A., Ketterling R. P., Brockman S. R., Flynn H. C., Paternoster S. F., Shearer B. M.,Reeder T. L., Li C. Y., Cross N. C., Cools J., Gilliland D.
G., Dewald G. W., Tefferi A.CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosisassociated with eosinophilia and predicts response to imatinib mesylate therapy // Blood. ‒2003. ‒ T. 102, № 9. ‒ C. 3093-6.215.
Klion A. D., Noel P., Akin C., Law M. A., Gilliland D. G., Cools J., Metcalfe D. D., Nutman T.B. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variantof idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, andimatinib responsiveness // Blood. ‒ 2003. ‒ T. 101, № 12. ‒ C.
4660-6.216. Valent P., Escribano L., Broesby-Olsen S., Hartmann K., Grattan C., Brockow K., NiedoszytkoM., Nedoszytko B., Oude Elberink J. N., Kristensen T., Butterfield J. H., Triggiani M.,Alvarez-Twose I., Reiter A., Sperr W. R., Sotlar K., Yavuz S., Kluin-Nelemans H. C.,Hermine O., Radia D., van Doormaal J. J., Gotlib J., Orfao A., Siebenhaar F., Schwartz L.
B.,Castells M., Maurer M., Horny H. P., Akin C., Metcalfe D. D., Arock M. Proposed diagnosticalgorithm for patients with suspected mastocytosis: a proposal of the European CompetenceNetwork on Mastocytosis // Allergy. ‒ 2014. ‒ T. 69, № 10. ‒ C. 1267-74.217. Kempf W., Reichlin S., Burg G. HistoClinC: a Web-based telemedicine application forclinicopathologic correlations in dermatopathology // Curr Probl Dermatol. ‒ 2003. ‒ T. 32. ‒C. 213-20.218. Jara-Acevedo M., Teodosio C., Sanchez-Munoz L., Alvarez-Twose I., Mayado A., Caldas C.,Matito A., Morgado J.
M., Munoz-Gonzalez J. I., Escribano L., Garcia-Montero A. C., OrfaoA. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis:diagnostic implications // Mod Pathol. ‒ 2015. ‒ T. 28, № 8. ‒ C. 1138-49.147219. Zhang L. Y., Smith M. L., Schultheis B., Fitzgibbon J., Lister T. A., Melo J. V., Cross N. C.,Cavenagh J.
D. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro andin vivo responsiveness to imatinib therapy // Leuk Res. ‒ 2006. ‒ T. 30, № 4. ‒ C. 373-8.220. de Melo Campos P., Machado-Neto J. A., Scopim-Ribeiro R., Visconte V., Tabarroki A., DuarteA. S., Barra F. F., Vassalo J., Rogers H. J., Lorand-Metze I., Tiu R. V., Costa F.
F., OlallaSaad S. T., Traina F. Familial systemic mastocytosis with germline KIT K509I mutation issensitive to treatment with imatinib, dasatinib and PKC412 // Leuk Res. ‒ 2014. ‒ T. 38, № 10.‒ C. 1245-51.221. Ke H., Kazi J. U., Zhao H., Sun J. Germline mutations of KIT in gastrointestinal stromal tumor(GIST) and mastocytosis // Cell Biosci.
‒ 2016. ‒ T. 6. ‒ C. 55.222. Jogie-Brahim S., Min H. K., Fukuoka Y., Xia H. Z., Schwartz L. B. Expression of alpha-tryptaseand beta-tryptase by human basophils // J Allergy Clin Immunol. ‒ 2004. ‒ T. 113, № 6. ‒ C.1086-92.223. Schwartz L. B., Bradford T. R., Rouse C., Irani A. M., Rasp G., Van der Zwan J. K., Van derLinden P. W.
Development of a new, more sensitive immunoassay for human tryptase: use insystemic anaphylaxis // J Clin Immunol. ‒ 1994. ‒ T. 14, № 3. ‒ C. 190-204.224. Sperr W. R., Jordan J. H., Fiegl M., Escribano L., Bellas C., Dirnhofer S., Semper H.,Simonitsch-Klupp I., Horny H. P., Valent P. Serum tryptase levels in patients withmastocytosis: correlation with mast cell burden and implication for defining the category ofdisease // Int Arch Allergy Immunol.
‒ 2002. ‒ T. 128, № 2. ‒ C. 136-41.225. Alvarez-Twose I., Vano-Galvan S., Sanchez-Munoz L., Morgado J. M., Matito A., Torrelo A.,Jaen P., Schwartz L. B., Orfao A., Escribano L. Increased serum baseline tryptase levels andextensive skin involvement are predictors for the severity of mast cell activation episodes inchildren with mastocytosis // Allergy. ‒ 2012. ‒ T. 67, № 6.
‒ C. 813-21.226. Barete S., Assous N., de Gennes C., Grandpeix C., Feger F., Palmerini F., Dubreuil P., Arock M.,Roux C., Launay J. M., Fraitag S., Canioni D., Billemont B., Suarez F., Lanternier F.,Lortholary O., Hermine O., Frances C. Systemic mastocytosis and bone involvement in acohort of 75 patients // Ann Rheum Dis. ‒ 2010. ‒ T. 69, № 10. ‒ C.
1838-41.227. Azana J. M., Torrelo A., Mediero I. G., Zambrano A. Urticaria pigmentosa: a review of 67pediatric cases // Pediatr Dermatol. ‒ 1994. ‒ T. 11, № 2. ‒ C. 102-6.228. Castells M., Metcalfe D. D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis inchildren: practical recommendations // Am J Clin Dermatol. ‒ 2011. ‒ T. 12, № 4. ‒ C.
259-70.229. Carter M. C., Metcalfe D. D. Paediatric mastocytosis // Arch Dis Child. ‒ 2002. ‒ T. 86, № 5. ‒C. 315-9.148230. Gulen T., Akin C. Pharmacotherapy of mast cell disorders // Curr Opin Allergy Clin Immunol. ‒2017. ‒ T. 17, № 4. ‒ C. 295-303.231. Siebenhaar F., Akin C., Bindslev-Jensen C., Maurer M., Broesby-Olsen S.
Treatment strategies inmastocytosis // Immunol Allergy Clin North Am. ‒ 2014. ‒ T. 34, № 2. ‒ C. 433-47.232. Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions butdifficult to manage) // Blood. ‒ 2013. ‒ T. 121, № 16. ‒ C. 3085-94.233. Gonzalez-de-Olano D., Matito A., Orfao A., Escribano L. Advances in the understanding andclinical management of mastocytosis and clonal mast cell activation syndromes // F1000Res. ‒2016.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
